Navigation Links
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Date:9/4/2009

SEATTLE, Sept. 4 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following four upcoming investor conferences.

    Rodman & Renshaw 11th Annual Health Care Conference
    Wednesday, September 9, 2009
    4:05 p.m. ET

    Morgan Stanley 2009 Global Health Care Unplugged Conference
    Tuesday, September 15, 2009
    8:35 a.m. ET

    BioCentury 16th Annual NewsMakers in the Biotech Industry Conference
    Wednesday, September 16, 2009
    1:30 p.m. ET

    UBS 2009 Global Life Sciences Conference
    Wednesday, September 23, 2009
    1:00 p.m. ET

The presentations at Rodman & Renshaw, BioCentury NewsMakers and UBS will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... A compact PET scanner called ... MRI (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and MRI are ... animal subjects. Simultaneous PET/MRI imaging offers a solution to many challenges that face ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron Cushman ... an associate in the firm’s Intellectual Property practice group. , Clients turn to ... applications. He has an electrical engineering and computer engineering background, and experience in ...
(Date:4/26/2016)... ... April 26, 2016 , ... This unique "Fertility Happy ... will offer attendees an opportunity to get the lowdown on female fertility and the ... and appetizers, Dr. Jesse Hade, of Boston IVF - The Arizona Center, will give ...
(Date:4/26/2016)... Seattle, Washington (PRWEB) , ... April 26, 2016 ... ... based non-profit, today announced the opening of its first round of pre-proposal competition ... thinking. The organization seeks to identify ideas with the highest potential to ...
Breaking Biology Technology:
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
(Date:3/3/2016)... and DE SOTO, Kansas ... U.S.-based Stroke Detection Plus® to offer Oncimmune,s Early ... assessment and early detection of lung cancer ... employers, unions and individuals. --> Early CDT®-Lung ... and individuals. --> Oncimmune, a leader in ...
Breaking Biology News(10 mins):